# Bill as Introduced

#### HB 657 - AS AMENDED BY THE HOUSE

19Mar2019... 0906h

#### 2019 SESSION

19-0801 · 01/03

HOUSE BILL

657

AN ACT

relative to prescription drugs under the managed care law.

SPONSORS:

Rep. Butler, Carr. 7; Rep. Marsh, Carr. 8; Rep. Knirk, Carr. 3; Rep. Hennessey,

Graf. 1; Sen. Sherman, Dist 24

COMMITTEE:

Commerce and Consumer Affairs

#### AMENDED ANALYSIS

This bill clarifies the law regarding prescription drugs under the managed care law.

Explanation:

Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

19-0801 01/03

#### STATE OF NEW HAMPSHIRE

#### In the Year of Our Lord Two Thousand Nineteen

AN ACT

relative to prescription drugs under the managed care law.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, II through III to read as follows:

II. Every health benefit plan that provides prescription drug benefits shall maintain an expeditious exception process, not to exceed 48 hours, by which covered persons may obtain coverage for a medically necessary nonformulary prescription drug or for a nonformulary prescription drug that was available during the previous 12 months. The exception process shall begin when the prescribing provider has submitted a request with a clinical rationale for the exception to the health benefit plan. The exception process shall also begin when a covered person has submitted a non-clinical request for access to a drug approved by the federal Food and Drug Administration for treating a specific condition when such drug was available on the formulary during the previous 12 months. A prescription that requires an exception for coverage shall be considered approved if the exception process exceeds 48 hours.

II-a. No health benefit plan that provides prescription drug benefits and establishes the specific sequence in which prescription drugs for a medical condition are to be prescribed shall require failure on the same medication on more than one occasion for patients continuously enrolled in the plan. Nothing in this section shall be construed to prevent a health care provider from prescribing a medication to the same patient on more than one occasion, when he or she determines it is medically appropriate.

III. Every health plan that provides prescription drug benefits shall [notify] provide written notice in a conspicuous font and size to covered persons affected by deletions to the plan list or plan formulary, provide an explanation of the exception process by which a covered person can access nonformulary medically necessary prescription drugs, and provide a toll-free telephone number through which a covered person can request additional information. For purposes of this paragraph, covered persons affected by deletions to the plan list or plan formulary shall include those covered persons for whom the health plan has provided coverage for the deleted prescription drugs during the 12-month period immediately prior to the deletion. Upon notification to covered persons, the health benefit plan shall allow at least 45 days before implementation of any formulary deletions; provided, however, that advance notice shall not be required if the federal Food and Drug Administration has determined that a prescription drug on the health benefit plan's formulary is unsafe. For purposes of this section, "conspicuous font and size" shall mean a font that is at least 12 point in size and in an easily legible font. If a covered person avails him or

### HB 657 - AS AMENDED BY THE HOUSE - Page 2 -

herself of the exception process as outlined in 420-J:7-b, II, the medication shall be covered by the health plan until there is a resolution of the exception process.

2 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, IX(a) to read as follows:

IX.(a) Every health benefit plan that provides prescription drug benefits shall allow its covered persons to obtain an emergency prescription for up to a 72-hour supply of covered prescription drugs on the covered person's health benefit plan formulary or a prescription drug that was deleted from the formulary within the last 90 days in the event a prescription requires prior authorization or an exception by an insurance carrier and the prior authorization or exception has neither been approved nor denied and a pharmacist has determined the medication is essential as provided in RSA 318:47-i. Such reimbursement shall be according to the payment rates of the provider contract. If authorization or exception is subsequently denied, the carrier shall reimburse the pharmacist for the prescription as given based on the pro-rated amount they would have otherwise received under the terms of the provider contract.

3 Effective Date. This act shall take effect 60 days after its passage.

# HB 657 FISCAL NOTE AS AMENDED BY THE HOUSE (AMENDMENT #2019-0906h)

ΔN	J	Δ	$C^{y}$	T
n	v	$\boldsymbol{r}$	◡	1

relative to prescription drugs under the managed care law.

FISCAL IMPACT:

[X] State

[ ] County

[ ] Local

[ ] None

	Estimated Increase / (Decrease)				
STATE:	FY 2020	FY 2021	FY 2022	FY 2023	
Appropriation	\$0	\$0	\$0	\$0	
Revenue	Indeterminable	Indeterminable	Indeterminable	Indeterminable	
Expenditures	\$0	\$0	\$0	\$0	
Funding Source:	[X] General	[ ] Education	[ ] Highway	[ ] Other	

#### METHODOLOGY:

This bill establishes an exception for non formulary prescription drugs which were recently on a plan's formulary. The Insurance Department assumes that the bill may cause some inflationary pressure on claim costs since the formulary was structured to provide lower cost alternatives. The Department's consideration of the fiscal impact includes only the possible impact on insurance premium tax revenue.

The Department of Health of Humans Services states the bill is not applicable to Managed Care Programs and will have no fiscal impact to the Department.

#### AGENCIES CONTACTED:

Insurance Department and Department of Health and Human Services

#### **HB 657 - FINAL VERSION**

19Mar2019... 0906h 6Jun2019... 2350-EBA

#### 2019 SESSION

19-0801 01/03

HOUSE BILL

657

AN ACT

relative to prescription drugs under the managed care law.

SPONSORS:

Rep. Butler, Carr. 7; Rep. Marsh, Carr. 8; Rep. Knirk, Carr. 3; Rep. Hennessey,

Graf. 1; Sen. Sherman, Dist 24

COMMITTEE:

Commerce and Consumer Affairs

#### AMENDED ANALYSIS

This bill clarifies the law regarding prescription drugs under the managed care law.

Explanation:

Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

19Mar2019... 0906h 6Jun2019... 2350-EBA

19-0801 01/03

#### STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Nineteen

AN ACT

19 . 

relative to prescription drugs under the managed care law.

Be it Enacted by the Senate and House of Representatives in General Court convened:

- 1 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, II through III to read as follows:
- II. Every health benefit plan that provides prescription drug benefits shall maintain an expeditious exception process, not to exceed 48 hours, by which covered persons may obtain coverage for a medically necessary nonformulary prescription drug or for a nonformulary prescription drug that was available during the previous 12 months. The exception process shall begin when the prescribing provider has submitted a request with a clinical rationale for the exception to the health benefit plan. The exception process shall also begin when a covered person has submitted a non-clinical request for access to a drug approved by the federal Food and Drug Administration for treating a specific condition when such drug was available on the formulary during the previous 12 months. A prescription that requires an exception for coverage shall be considered approved if the exception process exceeds 48 hours.

II-a. No health benefit plan that provides prescription drug benefits and establishes the specific sequence in which prescription drugs for a medical condition are to be prescribed shall require failure on the same medication on more than one occasion for patients continuously enrolled in the plan. Nothing in this section shall be construed to prevent a health care provider from prescribing a medication to the same patient on more than one occasion, when he or she determines it is medically appropriate.

written notice in a conspicuous font and size to covered persons affected by deletions to the plan list or plan formulary, provide an explanation of the exception process by which a covered person can access nonformulary medically necessary prescription drugs, and provide a toll-free telephone number through which a covered person can request additional information. For purposes of this paragraph, covered persons affected by deletions to the plan list or plan formulary shall include those covered persons for whom the health plan has provided coverage for the deleted prescription drugs during the 12-month period immediately prior to the deletion. Upon notification to covered persons, the health benefit plan shall allow at least 45 days before implementation of any formulary deletions; provided, however, that advance notice shall not be required if the federal Food and Drug Administration has determined that a prescription drug on the health benefit plan's formulary is unsafe. For purposes of this section, "conspicuous font and size" shall mean a font that is

### HB 657 - FINAL VERSION - Page 2 -

at least 12 point in size and in an easily legible font. If a covered person avails himself or herself of the exception process as outlined in 420-J:7-b, II, the medication shall be covered by the health plan until there is a resolution of the exception process.

2 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, IX(a) to read as follows:

IX.(a) Every health benefit plan that provides prescription drug benefits shall allow its covered persons to obtain an emergency prescription for up to a 72-hour supply of covered prescription drugs on the covered person's health benefit plan formulary or a prescription drug that was deleted from the formulary within the last 90 days in the event a prescription requires prior authorization or an exception by an insurance carrier and the prior authorization or exception has neither been approved nor denied and a pharmacist has determined the medication is essential as provided in RSA 318:47-i. Such reimbursement shall be according to the payment rates of the provider contract. If authorization or exception is subsequently denied, the carrier shall reimburse the pharmacist for the prescription as given based on the pro-rated amount they would have otherwise received under the terms of the provider contract.

3 Effective Date. This act shall take effect 60 days after its passage.

#### CHAPTER 180 HB 657 - FINAL VERSION

19Mar2019... 0906h 6Jun2019... 2350-EBA

#### 2019 SESSION

19-0801 01/03

HOUSE BILL

657

AN ACT

relative to prescription drugs under the managed care law.

SPONSORS:

Rep. Butler, Carr. 7; Rep. Marsh, Carr. 8; Rep. Knirk, Carr. 3; Rep. Hennessey,

Graf. 1; Sen. Sherman, Dist 24

COMMITTEE:

Commerce and Consumer Affairs

#### AMENDED ANALYSIS

This bill clarifies the law regarding prescription drugs under the managed care law.

Explanation:

Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

#### CHAPTER 180 HB 657 - FINAL VERSION

19Mar2019... 0906h 6Jun2019... 2350-EBA

19-0801 01/03

#### STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Nineteen

AN ACT

relative to prescription drugs under the managed care law.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 180:1 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, II through III to read as 2 follows:

II. Every health benefit plan that provides prescription drug benefits shall maintain an expeditious exception process, not to exceed 48 hours, by which covered persons may obtain coverage for a medically necessary nonformulary prescription drug or for a nonformulary prescription drug that was available during the previous 12 months. The exception process shall begin when the prescribing provider has submitted a request with a clinical rationale for the exception to the health benefit plan. The exception process shall also begin when a covered person has submitted a non-clinical request for access to a drug approved by the federal Food and Drug Administration for treating a specific condition when such drug was available on the formulary during the previous 12 months. A prescription that requires an exception for coverage shall be considered approved if the exception process exceeds 48 hours.

II-a. No health benefit plan that provides prescription drug benefits and establishes the specific sequence in which prescription drugs for a medical condition are to be prescribed shall require failure on the same medication on more than one occasion for patients continuously enrolled in the plan. Nothing in this section shall be construed to prevent a health care provider from prescribing a medication to the same patient on more than one occasion, when he or she determines it is medically appropriate.

III. Every health plan that provides prescription drug benefits shall [netify] provide written notice in a conspicuous font and size to covered persons affected by deletions to the plan list or plan formulary, provide an explanation of the exception process by which a covered person can access nonformulary medically necessary prescription drugs, and provide a toll-free telephone number through which a covered person can request additional information. For purposes of this paragraph, covered persons affected by deletions to the plan list or plan formulary shall include those covered persons for whom the health plan has provided coverage for the deleted prescription drugs during the 12-month period immediately prior to the deletion. Upon notification to covered persons, the health benefit plan shall allow at least 45 days before implementation of any formulary deletions; provided, however, that advance notice shall not be required if the federal Food and Drug Administration has determined that a prescription drug on the health benefit plan's formulary is

#### CHAPTER 180 HB 657 - FINAL VERSION - Page 2 -

unsafe. For purposes of this section, "conspicuous font and size" shall mean a font that is at least 12 point in size and in an easily legible font. If a covered person avails himself or herself of the exception process as outlined in 420-J:7-b, II, the medication shall be covered by the health plan until there is a resolution of the exception process.

180:2 Managed Care Law; Prescription Drugs. Amend RSA 420-J:7-b, IX(a) to read as follows:

IX.(a) Every health benefit plan that provides prescription drug benefits shall allow its covered persons to obtain an emergency prescription for up to a 72-hour supply of covered prescription drugs on the covered person's health benefit plan formulary or a prescription drug that was deleted from the formulary within the last 90 days in the event a prescription requires prior authorization or an exception by an insurance carrier and the prior authorization or exception has neither been approved nor denied and a pharmacist has determined the medication is essential as provided in RSA 318:47-i. Such reimbursement shall be according to the payment rates of the provider contract. If authorization or exception is subsequently denied, the carrier shall reimburse the pharmacist for the prescription as given based on the pro-rated amount they would have otherwise received under the terms of the provider contract.

180:3 Effective Date. This act shall take effect 60 days after its passage.

Approved: July 10, 2019

Effective Date: September 08, 2019

# Committee Minutes

# SENATE CALENDAR NOTICE Commerce

Sen Kevin Cavanaugh, Chair Sen Jon Morgan, Vice Chair Sen Donna Soucy, Member Sen Chuck Morse, Member Sen Harold French, Member

Date: April 18, 2019

#### **HEARINGS**

Thursday	04/25/2019		
(Day)	(Dat	re)	
Commerce	SH 100	1:00 p.m.	
(Name of Committee)	(Place)	(Time)	

Note: The Committee will meet at 1:00 p.m. or 30 minutes following the end of Session.

1:00 p.m.	HB 695	relative to transparency of nonprofit patient advocacy organizations.
1:15 p.m.	HB 402	relative to required notice of mortgage funding at a construction jobsite.
1:30 p.m.	HB 654	relative to surety required on construction loans.
1:45 p.m.	HB 740	exempting certain mortgages from the law regarding licensing of nondepository mortgage bankers, brokers, and servicers.
2:00 p.m.	HB 268	relative to real estate commissions paid to unlicensed entities.
2:15 p.m.	HB 657	relative to prescription drugs under the managed care law.

#### EXECUTIVE SESSION MAY FOLLOW

Sponsors: HB 695 Rep. McBeath

HB 402

Rep. Flanagan HB 654

Rep. Butler HB 740 Rep. Butler

HB 268 Rep. Baroody

Rep. Hinch

Rep. DiSilvestro

Sen. Carson

HB 657

Rep. Butler Rep. Marsh Sen, Sherman

Rep. Knirk

Rep. Hennessey

Laura Bryant 271-1403

<u>Kevin Cavanaugh</u> Chairman

#### **Senate Commerce Committee**

Laura Bryant 271-1403

HB 657, relative to prescription drugs under the managed care law.

Hearing Date:

April 25, 2019

Time Opened:

12:30 p.m.

Time Closed:

Members of the Committee Present: Senators Cavanaugh, Morse, Soucy and

French

Members of the Committee Absent: Senator Morgan

Bill Analysis: This bill clarifies the law regarding prescription drugs under the

managed care law.

Sponsors:

Rep. Butler

Rep. Marsh

Rep. Knirk

Rep. Hennessey

Sen. Sherman

Who supports the bill: None

Who opposes the bill: None

Who is neutral on the bill: None

Summary of testimony presented:

Senator Soucy, on behalf of Representative Butler, introduced the bill and read it's analysis. No one else was present to testify on the bill, and none of the committee members asked questions.

LHB

Date Hearing Report completed: April 25, 2019

# SENATE CALENDAR NOTICE Commerce

Sen Kevin Cavanaugh, Chair Sen Jon Morgan, Vice Chair Sen Donna Soucy, Member Sen Chuck Morse, Member Sen Harold French, Member

Date: April 25, 2019

#### **HEARINGS**

Tuesday		04/30/201	04/30/2019			
(Day)		(Date)				
Commerce	e	LOB 102	1:00 p.m.			
(Name of Committee)		(Place)	(Time)			
1:00 p.m.	HB 233	relative to the group and individual health insu	ırance market.			
1:15 p.m.	HB 536-FN	adding biometric information to the consumer protection act.				
1:30 p.m.	HB 725-FN	relative to certain standards for managed care organizations.				
1:45 p.m.	HB 558-FN	restricting the distribution of plastic straws.				
2:15 p.m.	HB 560-FN	relative to single-use carryout bags.				
2:45 p.m.	HB 695	relative to transparency of nonprofit patient ad (THE PREVIOUS HEARING FOR HB 695 WA APRIL 25th)				
3:00 p.m.	HB 657	relative to prescription drugs under the managed care law. (THE PREVIOUS HEARING FOR HB 657 WAS RECESSED ON APRIL 25th)				

Sponsors: HB 233 Rep. Butler Rep. Ticehurst Rep. Knirk Rep. Marsh Rep. Campion Rep. Cushing Rep. Luneau Rep. Berrien Sen. Bradley Sen. Rosenwald Sen. Hennessey Sen. Sherman **HB 536-FN** Rep. Luneau Rep. Hunt Sen. Cavanaugh HB 725-FN Rep. Knirk Sen. Sherman Rep. Woods Rep. Williams Rep. Marsh HB 558-FN Rep. Spang Rep. Luneau Rep. Myler Rep. Balch Sen. Fuller Clark Sen, Watters **HB 560-FN** Rep. Myler Rep. Balch Rep. Luneau Rep. Spang Sen. Fuller Clark Sen. Watters HB 695 Rep. McBeath HB 657 Rep. Butler Rep. Knirk Rep. Hennessey Rep. Marsh Sen. Sherman

Laura Bryant 271-1403

Kevin Cavanaugh Chairman

# SENATE CALENDAR NOTICE Commerce

Sen Kevin Cavanaugh, Chair Sen Jon Morgan, Vice Chair Sen Donna Soucy, Member Sen Chuck Morse, Member Sen Harold French, Member

Date: May 2, 2019

#### **HEARINGS**

Tuesday		05/07/2	019	
	(Day)	(Date	e) ·	
Commerce	•	SH 100	1:00 p.m.	
(Name of	Committee)	(Place)	(Time)	
1:00 p.m.	HB 695	relative to transparency of nonprofit patient (THE PREVIOUS HEARING FOR HB 695 W APRIL 30th)		
1:15 p.m.	HB 657	relative to prescription drugs under the man (THE PREVIOUS HEARING FOR HB 657 W APRIL 30th)		
1:30 p.m.	HB 656	establishing a commission to study the impact of financial initiati for commercially insured members by drug manufacturers on prescription drug prices and health insurance premiums.		
1:45 p.m.	HB 277	establishing a commission to study a public of insurance.	option for health	
2:00 p.m.	HB 577	relative to call blocking in an automated tele	phone dialing system.	
2:15 p.m.	HB 703-FN	relative to providing notice of the introduction prescription drugs.	n of new high-cost	

Sponsors: HB 695 Rep. McBeath HB 657 Rep. Butler

Sen. Sherman

Rep. Marsh

Rep. Knirk

Rep. Hennessey

HB 656

Rep. Butler Sen. Bradley Rep. Marsh Sen. Sherman Rep. Knirk

Rep. Hennessey

HB 277

Rep. Knirk Sen. Sherman

Rep. Nutting-Wong Sen. Hennessey

Rep. Campion

Rep. Fothergill

HB 577

Rep. Luneau HB 703-FN Rep. Gordon

Rep. Butler

Rep. Knirk

Sen, Sherman

Laura Bryant 271-1403

Kevin Cavanaugh Chairman

#### Senate Commerce Committee

Laura Bryant 271-1403

HB 657, relative to prescription drugs under the managed care law.

Hearing Date:

May 7, 2019

Time Opened:

1:27 p.m.

Time Closed:

1:32 p.m.

Members of the Committee Present: Senators Cavanaugh, Soucy, and Morse Members of the Committee Absent: Senators Morgan and French

Bill Analysis: This bill clarifies the law regarding prescription drugs under the managed care law.

Sponsors:

Rep. Butler

Rep. Marsh

Rep. Knirk

Rep. Hennessey

Sen. Sherman

Who supports the bill: Paula Rogers with Anthem, Senator Tom Sherman, Holly Stevens with New Futures

Who opposes the bill: None

Who is neutral on the bill: Tyler Brannen with NHID

Summary of testimony presented:

#### Holly Stevens with New Futures:

- Stevens said that this bill is a direct result of testimony from the commission that was created by HB 1418.
- She said that the commission made no recommendations, however, someone testified that they were on a medication and then it was taken off their formulary, only to then be put on a higher priced medication. This led to them having to fight to get back on the cheaper medication.
- She said that the amendment allows an exception so someone can be on a medication for a non-clinical reason if the medication was previously on their formulary in the last 12 months.
- She stated that this would also allow them to get an emergency 72-hour supply of the prescription filled once they begin the exception process.

# Tyler Brannen, Director of Health Economics with the NH Insurance Department:

Brannen stated that the department does regulate pharmacy benefit managers

and insurance companies that administer the medications on someone's formulary, but their oversight is largely limited to seeing if the formulary is discriminatory or not, like if a formulary didn't cover any medications for someone diagnosed with HIV or AIDS.

• He said that this bill gives the patient more choice when it comes to medication.

Senator Soucy asked about the placement of this bill in the statute and how this would apply to self-insured plans.

• Brannen said that this bill would not apply to the self-insured market.

Senator Soucy noted that the example that Holly Stevens cited was a state employee covered by the state, and asked if that meant that this bill wouldn't apply to someone in a similar circumstance.

• Brannen replied that indeed it wouldn't and that generally it wouldn't be subject to state law. He said these laws are permissible if it doesn't change the benefit that the employer has bought, but in that case it would be preempted by federal law.

LHB
Date Hearing Report completed: May 8, 2019

# Speakers

### **Senate Commerce Committee**

SIGN-IN SHEET, Public Hearing HB 657

Date:

4/30/19

**Time:** 3:00 p.m

Name/Representing (please print neatly)					
SUSAN COVERT CONTOCOCK SELF	Support	Oppose	Speaking?	Yes	No D
Holly Stevens New Fatures	Support	Oppose	Speaking?	Yes	No
Paula Rogers - Anthem	Support	Oppose	Speaking?	Yes	No.
Sen. Tom Sherman SD24	Support	Oppose	Speaking?	Yes	No
hourse Spencer Self	Support	Oppose	Speaking?	Yes	N <sub>0</sub>
John Williams (submitting) DHHS	Support	Oppose	Speaking?	Yes	No
Tyles Bannen WHY	Support	Oppose	Speaking?	Yes	No
0	Support	Oppose	Speaking?	Yes	No
	Support	Oppose ·	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
·	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No U
	Support	Oppose	Speaking?	Yes	No

### **Senate Commerce Committee** SIGN-IN SHEET, Public Hearing HB 657

Date:

5/7/19

**Time:** 1:15 p.m

Name/Representing (please print neatly)					
Sen. Tom Sherman 15D24	Support	Oppose	Speaking?	Yes	No
Holly Stevens	Support 🔽	Oppose	Speaking?	Yes L	No □
V Titer Branney NHID	Support	Oppose	Speaking?	Yes	No □
A podell	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No □
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No □
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
, , , , , , , , , , , , , , , , , , ,	Support	Oppose	Speaking?	Yes	N <sub>o</sub>
	Support	Oppose	Speaking?	Yes	No 🗆
	Support	Oppose	Speaking?	Yes	No □
	Support	Oppose	Speaking?	Yes	No □
-	Support	Oppose	Speaking?	Yes	
	Support	Oppose	Speaking?	Yes	No □
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No □
	Support	Oppose	Speaking?	Yes	No

# Senate Commerce Committee

SIGN-IN SHEET, Public Hearing HB 657

Date:

5/7/19

**Time:** 1:15 p.m

Name/Representing (please print neatly)					
PAULA ROGERS ANTHEM	Support	$ \qquad \qquad \square$	Speaking?	Yes	No Z
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support $\square$	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
<u>.                                    </u>	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	$ \qquad \qquad \square$	Speaking?	Yes	No
<u> </u>	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No
	Support	Oppose	Speaking?	Yes	No

# Testimony



Jeffrey A. Meyers Commissioner

Henry D. Lipman Director

# STATE OF NEW HAMPSHIRE DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **DIVISION OF MEDICAID SERVICES**

129 PLEASANT STREET, CONCORD, NH 03301 603-271-9422 1-800-852-3345 Ext. 9422 Fax: 603-271-8431 TDD Access: 1-800-735-2964 www.dbhs.nh.gov

April 29, 2019

Honorable Senator Kevin Cavanaugh, Chair Senate Commerce Committee State House, Room 100 107 North Main Street Concord, NH 03301

RE: HB 657, an act relative to prescription drugs under the managed care law.

Dear Senator Cavanaugh:

The purpose of this communication is to inform you and members of the Senate Commerce Committee that the New Hampshire Department of Health and Human Services ("DHHS") does not take a position on HB 657, (as amended by the House), because the legislation does not apply to DHHS. As passed by the House, HB 657 amends various paragraphs of RSA 420-J:7-b, the section of the Managed Care Law that governs prescription drugs. RSA 420-J:7-b, IV-c, (g) affirmatively states "This section [RSA 420-J: 7-b] shall apply to RSA 420-J and shall not apply to the Medicaid managed care program under RSA 126-A:5, XIX."

By way of additional background, I note that DHHS is the administrating entity for the our state-federal Medicaid program which provides a prescription drug benefit to approximately 180,000 New Hampshire residents served by the Medicaid program. Pursuant to various statutory provisions, DHHS contracts with managed care organizations to provide health care services, including prescription drugs, to Medicaid recipients enrolled in Medicaid managed care organizations. The managed care organizations with which DHHS contracts are subject to the relevant provisions of federal and state Medicaid law, state insurance law, and the terms and conditions of the contracts with DHHS. DHHS is not subject to regulation by the New Hampshire Insurance Department as an insurance carrier or as a health benefit plan.

Please do not hesitate to contact me if you and or your committee members have any questions or wish additional information from DHHS. I may be reached at (603) 271-9434 or at <a href="https://henry.lipman@dhhs.nh.gov">henry.lipman@dhhs.nh.gov</a>. Thank you for your consideration of these comments.

Sincerely.

Henry D./Lipman,/FACHE Nedicaid Director

cc: Honorable members of the Senate Commerce Committee Representative Ed Butler, prime sponsor



## advocate • educate • collaborate to improve the health and wellness of all Granite Staters

April 25, 2019

The Honorable Kevin Cavanaugh, Chairman Senate Commerce Committee State House Room 100 Concord, NH 03301

Re: New Futures' support of HB 657

Dear Chairman Cavanaugh and Members of the Committee:

New Futures appreciates the opportunity to testify in support of HB 657 as amended by the House, which would expand the formulary exception process to include any drug that was removed from the formulary in the past 12 months even when that drug is not medically necessary. New Futures is a nonpartisan, nonprofit organization that advocates, educates and collaborates to improve the health and wellness of all New Hampshire residents. In this role, we work extensively with policy makers, health care providers and families to increase access to quality, affordable health care throughout the Granite State.

Last summer, I participated in the HB 1418 Commission to Study Greater Transparency in Pharmaceutical Costs and Drug Rebate Programs (Commission). Although the Commission heard testimony from many stakeholders, it did not have enough time to complete its study. The Commission was not able to come to a consensus around any legislative recommendations; however, individual Commission members did make suggestions for legislative change. One thing that was clear from the testimony is that increasing drug prices are not the result of any one entity type (i.e. manufacturers, PBM, insurers, etc.), but due to what is going on in the entire system. The problem is, the system is very opaque, and no one can see what is truly causing the skyrocketing prices.

One of the legislative suggestions that resulted from the Commission was that health insurance plans would be required to include on their formularies the lowest cost option for the insured. A consumer testified that she was on a certain medication. She stated that it was removed from the formulary and was replaced by a drug that had a higher out of pocket cost to her. Not only was this medication a higher cost to her, it was a higher cost to her insurer. The medication she had been on cost much less than the one she was now required to be on. She was able to advocate for herself and have the insurer cover the less expensive medication. The thing that doesn't make sense is why the insurer stopped covering the medication in the first place, replacing it with a medication that was more expensive for everyone. HB 657 as introduced was meant to address this issue.

During work sessions on HB 657 when the bill was in House Commerce and Consumer Affairs, it became clear that the bill as drafted would be unworkable. Although great in theory, practically speaking, it would be impossible to implement. The stakeholders, including the insurers, some of the Pharmacy Benefit Managers, and New Futures met to discuss language that would address the issue raised during the Commission. The consensus of the stakeholders was expanding the current formulary exception process to include exceptions for non-clinical reasons if the drug had been on the formulary in the previous 12 months. It also changes the notice process when a drug is removed

from the formulary requiring the notice to be written and in a conspicuous font and size. If further expands the emergency 72-hour supply law to include drugs that were deleted from the formulary in the past 90 days if that drug would require an exception for the consumer to remain on it. Ninety days was chosen because that is the most amount of time that should pass before a consumer becomes aware that a medication has been deleted from the formulary, and it will allow the consumer to receive a 72-hour supply while availing him or herself of the exception process.

HB 657 as amended by the House was a collaboration by the stakeholders with all agreeing to the language. Additionally, it will remedy the issue brought up by the consumer during hearings of the HB 1418 Commission. For these reasons, New Futures urges the Committee to vote HB 657 ought to pass.

Please do not hesitate to contact me if you have any questions.

Respectfully submitted,

Holly A. Stevens, Esq.

Health Policy Coordinator

# Voting Sheets

## Senate Commerce Committee

# EXECUTIVE SESSION RECORD $2019\text{-}2020\ Session$

Bill # 657	
Hearing date:	
Executive Session date: 5 M 119	
Motion of:	_
Committee Member Made by Second Yes No	
Sen Cavanaugh,	
Sen. Morgan, V- Chair	
Sen. French	
Sen. Morse	
Sen. Soucy	
Motion of: Corgue Vote: 5-7	>
Committee Member Made by Second Yes No	_
Sen. Cavanaugh,	
Chair	
Sen. Morgan, V-Chair	
Sen. French	
Sen. Morse	
Sen. Soucy	
Motion of: Vote:	
Committee Member Made by Second Yes No	_
Sen. Cavanaugh	
Sen. Cavanaugh. Chair	
Sen. Morgan, V- Chair	
Sen. French	
Sen. Morse	
Sen. Soucy	
•	
Reported out by:	

# Committee Report

#### STATE OF NEW HAMPSHIRE

#### SENATE

# REPORT OF THE COMMITTEE FOR THE CONSENT CALENDAR

Thursday, May 16, 2019

#### THE COMMITTEE ON Commerce

to which was referred HB 657

AN ACT

relative to prescription drugs under the managed care law.

Having considered the same, the committee recommends that the Bill

**OUGHT TO PASS** 

BY A VOTE OF: 5-0

Senator Kevin Cavanaugh For the Committee

This bill clarifies the law regarding prescription drugs under the managed care law. The committee supports this bill because it will help in lowering prescription drug costs for patients by expanding the formulary exception process to include any drug that has been removed from a patient's formulary in the last 12 months even if it is not for a medically necessary reason.

Laura Bryant 271-1403

#### FOR THE CONSENT CALENDAR

#### **COMMERCE**

HB 657, relative to prescription drugs under the managed care law. Ought to Pass, Vote 5-0.

Senator Kevin Cavanaugh for the committee.

This bill clarifies the law regarding prescription drugs under the managed care law. The committee supports this bill because it will help in lowering prescription drug costs for patients by expanding the formulary exception process to include any drug that has been removed from a patient's formulary in the last 12 months even if it is not for a medically necessary reason.

#### General Court of New Hampshire - Bill Status System

#### **Docket of HB657**

**Docket Abbreviations** 

Bill Title: (New Title) relative to prescription drugs under the managed care law.

Official Docket of HB657.:

Date	Body	Description
1/16/2019	Н	Introduced 01/03/2019 and referred to Commerce and Consumer Affairs HJ 3 P. 23
2/6/2019	Н	Public Hearing: 02/19/2019 10:15 am LOB 302
2/13/2019	Н	Subcommittee Work Session: 02/21/2019 10:30 am LOB 302
2/13/2019	Н	==RECESSED== Executive Session: 02/21/2019 02:00 pm LOB 302
2/27/2019	Н	Subcommittee Work Session: 03/06/2019 02:30 pm LOB 302
3/6/2019	Н	Subcommittee Work Session: 03/08/2019 09:00 am LOB 302-304
2/28/2019	Н	==CONTINUED== Executive Session: 03/08/2019 01:30 pm LOB 302-304
3/14/2019	Н	Committee Report: Ought to Pass with Amendment #2019-0906h (NT) for 03/19/2019 (Vote 20-0; CC) HC 16 P. 5
3/19/2019	н	Amendment #2019-0906h (NT): AA VV 03/19/2019 HJ 10 P. 13
3/19/2019	. н	Ought to Pass with Amendment 2019-0906h (NT): MA VV 03/19/2019 HJ 10 P. 13
4/1/2019	S	Introduced 03/28/2019 and Referred to Commerce; SJ 12
4/18/2019	S	==RECESSED== <b>Hearing:</b> 04/25/2019, Room 100, SH, 02:15 pm; <b>SC</b> 19
4/25/2019	S	==RECESSED== <b>Hearing:</b> 04/30/2019, Room 102, LOB, 03:00 pm; <b>SC 20</b>
5/2/2019	S	==RECONVENE== <b>Hearing:</b> 05/07/2019, Room 100, SH, 01:15 pm; <b>SC 21</b>
5/16/2019	S	Committee Report: Ought to Pass, 05/23/2019; Vote 5-0; CC SC 23
5/23/2019 .	S	Ought to Pass: MA, VV; OT3rdg; 05/23/2019; SJ 17
6/5/2019	S	Enrolled Bill Amendment #2019-2350e Adopted, VV, (In recess of 05/30/2019); SJ 19
6/6/2019	Н	Enrolled Bill Amendment #2019-2350e: AA VV 06/06/2019 HJ 18 P. 40
6/18/2019	S	Enrolled (In recess 06/13/2019); <b>SJ 21</b>
6/18/2019	Н.	Enrolled 06/13/2019 HJ 19 P. 18
7/15/2019	H	Signed by Governor Sununu 07/10/2019; Chapter 180; Eff: 09/08/2019

NH House	NH Senate

# Other Referrals

## Senate Inventory Checklist for Archives

Bill Number: #6 65/	Senate Committee: Commerco
Please include all documents in the order listed below	and indicate the documents which have been
included with an "X" beside	
Final docket found on Bill Status	
Bill Hearing Documents: {Legislative Aides}	
Bill version as it came to the committee	
All Calendar Notices	
Mearing Sign-up sheet(s)	
Prepared testimony, presentations, & other s	ubmissions handed in at the public hearing
K Hearing Report	
Kevised/Amended Fiscal Notes provided by the	ne Senate Clerk's Office
Committee Action Documents: {Legislative Aid	ne!
All amendments considered in committee (including	
amendment # ame	- · · · ·
amendment # ame	
Z Executive Session Sheet	
Committee Report	
Floor Action Documents: {Clerk's Office}	
All floor amendments considered by the body during	session (only if they are offered to the senate):
amendment # ame	
amendment # ame	
Post Floor Action: (if applicable) {Clerk's Office	<u>3</u>
Committee of Conference Report (if signed of by the committee of conference):	f by all members. Include any new language proposed
Enrolled Bill Amendment(s) 2350EBA	
Governor's Veto Message	
All available versions of the bill: {Clerk's Office	•
as amended by the senate	as amended by the house
final version	
Completed Committee Report File Delivered to	the Senate Clerk's Office By:
Committee Aide	Date
Senate Clerk's Office	

#### Enrolled Bill Amendment to HB 657

The Committee on Enrolled Bills to which was referred HB 657

AN ACT

relative to prescription drugs under the managed care law.

Having considered the same, report the same with the following amendment, and the recommendation that the bill as amended ought to pass.

FOR THE COMMITTEE	FOR	THE	COMM	<b>TTEE</b>
-------------------	-----	-----	------	-------------

#### Explanation to Enrolled Bill Amendment to HB 657

This enrolled bill amendment makes a grammatical correction.

#### Enrolled Bill Amendment to HB 657

Amend RSA 420-J:7-b, III as inserted by section 1 of the bill by replacing line 14 with the following:

 $himself\ or\ herself\ of\ the\ exception\ process\ as\ outlined\ in\ 420\mbox{-}J\mbox{-}7\mbox{-}b,\ II,\ the\ medication\ shall\ be$